Singapore markets open in 1 hour 37 minutes

Molecular Templates, Inc. (MTEM)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.2200+0.0400 (+3.39%)
At close: 04:00PM EDT
1.2200 0.00 (0.00%)
After hours: 06:39PM EDT

Molecular Templates, Inc.

9301 Amberglen Boulevard
Suite 100
Austin, TX 78729
United States
512 869 1555
https://www.mtem.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees62

Key executives

NameTitlePayExercisedYear born
Dr. Eric E. Poma Ph.D.CEO, Chief Scientific Officer & Director723.81kN/A1972
Ms. Jason S KimPresident, CFO, Treasurer & Principal Accounting Officer522.3kN/A1975
Ms. Kristen Quigley B.A.Chief Operating OfficerN/AN/A1971
Dr. Grace KimChief Strategy Officer & Head of IRN/AN/AN/A
Dr. Michelle Iwamoto-Fan J.D., Ph.D.Senior Vice President & General CounselN/AN/AN/A
Dr. Joseph Phillips Ph.D.Senior VP & Head of CMC DevelopmentN/AN/AN/A
Dr. Chris Moore Ph.D.Senior VP and Head of Preclinical Development & Translational MedicineN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Corporate governance

Molecular Templates, Inc.’s ISS governance QualityScore as of 29 May 2024 is 7. The pillar scores are Audit: 9; Board: 7; Shareholder rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.